Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction

Circulation

Volumn 117, Issue 20, 2008, Pages 2670-2683

  Abbate, Antonio ^a   Salloum, Fadi N ^a   Vecile, Elena ^f   Das, Anindita ^a   Hoke, Nicholas N ^a   Straino, Stefania ^a,d   Giuseppe, G L ^e   Biondi Zoccai, ^c   Houser, Jon Erik ^a   Qureshi, Ian Z ^a   Ownby, Evan D ^a   Gustini, Edoardo ^a,c   Biasucci, Luigi M ^b   Severino, Anna ^b   Capogrossi, Maurizio C ^d   Vetrovec, George W ^f   Crea, Filippo ^b   Baldi, Alfonso ^b   Kukreja, Rakesh C ^a   Dobrina, Aldo ^c  

^a Pauley Heart Center

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Apoptosis; Cytokine; Heart failure; Ischemia; Pharmacology; Remodeling

Indexed keywords

CASPASE 9; INTERLEUKIN 1BETA CONVERTING ENZYME; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ACUTE DRUG ADMINISTRATION; ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CORONARY ARTERY SURGERY; DISEASE SIMULATION; DRUG DOSE INCREASE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HEART CELL CULTURE; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; MALE; MOUSE; NONHUMAN; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; THERAPY DELAY; THERAPY EFFECT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; WISTAR RAT; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; HEART INFARCTION; MOUSE STRAIN; PATHOLOGY;

ANIMALS; APOPTOSIS; CASPASE 1; CASPASE 9; DISEASE MODELS, ANIMAL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MICE; MICE, INBRED STRAINS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; RATS; RATS, WISTAR;

EID: 47649105757     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.740233     Document Type: Article

References (44)

1. Abbate A, Bussani R, Amin MS, Vetrovec GW, Baldi A. Acute myocardial infarction and heart failure: role of apoptosis. Int J Biochem Cell Biol. 2006;38:1834-1840.
2. Severino A, Campioni M, Straino S, Salloum FN, Schmidt N, Herbrand U, Frede S, Toietta G, Di Rocco G, Bussani R, Silvestri F, Piro M, Liuzzo G, Biasucci LM, Mellone P, Feroce F, Capogrossi MC, Baldi F, Fandrey J, Ehrmann M, Crea F, Abbate A, Baldi A. Identification of protein disulfide isomerase (PDI) as a cardiomyocyte survival factor in ischemic cardiomyopathy. J Am Coll Cardiol. 2007;50:1029-1037.
3. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev. 1997;8: 253-265.
4. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
5. Patti G, D'Ambrosio A, Mega S, Giorgi G, Zardi EM, Zardi DM, Dicuonzo G, Dobrina A, Di Sciascio G. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43:35-38.
6. Patti G, Mega S, Pasceri V, Nusca A, Giorgi G, Zardi EM, D'Ambrosio A, Dobrina A, Di Sciascio G. Interleukin-1 receptor antagonist levels correlate with the extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol. 2005;28:193-196.
7. Airaghi L, Lettino M, Manfredi MG, Lipton JM, Catania A. Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy. Am Heart J. 1995;130:204-211.
8. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction of apoptosis. Circulation. 2001;104(suppl I): I-308-I-313.
9. Salloum FN, Abbate A, Das A, Houser J-E, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, Prabhakar S, Kukreja RC. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008;294: H1398-H1406.
10. Abbate A, Salloum FN, Ockaili RA, Fowler AA, Biondi-Zoccai GGL, Straino S, Lipinski MJ, Crea F, Biasucci LM, Vetrovec GW, Kukreja RC. Improvement of cardiac function with parecoxib, a cyclo-oxygenase-2 inhibitor, in a rat model of ischemic heart failure. J Cardiovasc Pharmacol. 2007;49:416-419.
11. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two- Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2: 358-367.
12. Tei C, Ling LH, Hodge DO, Bailey KR, Rodeheffer RJ, Tajik AJ, Seward JB. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function: a study in normals and dilated cardiomyopathy. Am J Cardiol. 1995; 26:357-366.
13. Abbate A, Bussani R, Biondi-Zoccai GGL, Santini D, Petrolini A, De Giorgio F, Vasaturo F, Scarpa S, Severino A, Liuzzo G, Leone AM, Baldi F, Sinagra G, Silvestri F, Vetrovec GW, Crea F, Biasucci LM, Baldi A. Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. Eur Heart J. 2005;26:2039-2045.
14. Creemers EEJM, Cleutjens JPM, Smits JFM, Daemen MJAP. Matrix metalloproteinase inhibition after myocardial infarction. Circ Res. 2001; 89:201-210.
15. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55- 62.
16. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of nitric oxide signaling. J Biol Chem. 2005;280: 12944-12955.
17. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ Jr. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A. 1998;95:2979-2984.
18. Cortes A, Cascante M, Cardenas ML, Cornish-Bowden A. Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data. Biochem J. 2001; 357:263-268.
19. Broberg CS, Pantely GA, Barber BJ, Mack GK, Lee K, Thigpen T, Davis LE, Sahn D, Hohimer AR. Validation the myocardial performance index by echocardiography in mice: a noninvasive measure of left ventricular function. J Am Soc Echocardiogr. 2003;16: 814- 823.
20. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA, Maseri A. Increasing levels of interleukin(IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99:2079-2084.
21. Patti G, Di Sciascio G, D'Ambrosio, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2002;89: 372-376.
22. Furst DE. Anakinra: review of recombinant human interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther. 2004;26: 1960-1975.
23. Dinarello CA. The role of interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med. 2000;343: 732-734.
24. Kineret product information. Available at: http://www.kineretrx.com/ pi.jsp#topPPI. Accessed March 16, 2008.
25. Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, Lucking AJ, Flather MD, Lees B, Foley CE. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (the MRC-ILA-HEART Study). Trials. 2008;9:8-14.
26. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, Tyrell PJ, for the Acute Stroke Investigators. A randomized phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005;76:1366-1372.
27. Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol. 2003;140:471- 476.
28. Garcia JH, Liu KF, Relton JK. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol. 1995;147:1477-1486.
29. Takadera T, Yumoto H, Tozuka Y, Ohyashiki T. Prostaglandin E2 induces caspase-dependent apoptosis in rat cortical cells. Neurosci Lett. 2002;317:61- 64.
30. Evans I, Dower SK, Francis SE, Crossman DC, Wilson HL. Action of intracellular IL-1Ra (type I) is independent of the IL-1 intracellular signalling pathway. Cytokine. 2006;33:274-280.
31. Wilson HL, Francis SE, Dower SK, Crossman DC. Secretion of intracellular IL-1 receptor antagonist (type I) is dependent on P2X7 receptor activation. J Immunol. 2004;173:1202-1208.
32. Nesic O, Xu GY, McAdoo D, High KW, Hulsebosch C, Perez-Polo R. IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J Neurotrauma. 2001;18:947-956.
33. Sun CC, Pang JHS, Cheng HF, Lee YS, Ku WC, Hsiao CH, Chen JK, Yang CM. Interleukin-1 receptor antagonist (IL-1RA) prevents apoptosis in ex vivo expansion of human limbal epithelial cells cultivated on human amniotic membrane. Stem Cells. 2006;24:2130-2139.
34. Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol. 2003;140:471- 476.
35. Morton AC, Arnold ND, Gunn J, Varcoe R, Francis SE, Dower SK, Crossman DC. Interleukin-1 receptor antagonist alters the response to vessel injury in a porcine coronary artery model. Cardiovasc Res. 2005; 68:493-501.
36. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997; 326:1-26.
37. Abbate A, Biondi-Zoccai GGL, Baldi A. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol. 2002;193:145-153.
38. Merkle S, Frantz S, Schon MP, Bauersachs J, Buitrago M, Frost RJA, Schmitteckert E, Lohse MJ, Engelhardt S. A role for caspase-1 in heart failure. Circ Res. 2007;100:645- 653.
39. Syed FM, Hahn HS, Odley A, Guo Y, Vallejo JG, Lynch RA, Mann DL, Bolli R, Dorn GW. Pro-apoptotic effects of caspase-1/interleukinconverting enzyme dominate in myocardial ischemia. Circ Res. 2005;96: 1103-1109.
40. Gottlieb R. ICE-ing the heart. Circ Res. 2005;96:1036-1038.
41. Fankhauser C, Friedlander RM, Gagliardini V. Prevention of nuclear localization of activated caspases correlates with inhibition of apoptosis. Apoptosis. 2000;5:117-132.
42. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992;4:353-360.
43. Larsen CM, Faulenbacj M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-1526.
44. Abbate A, Biondi-Zoccai GGL, Bussani R, Dobrina A, Camilot D, Feroce F, Rossiello R, Baldi F, Silvestri F, Biasucci LM, Baldi A. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol. 2003;41:753-760.